Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012
Rodríguez‐Gutiérrez, René , Montori, Víctor M. , Montori, Victor M

Annals of Internal Medicine | September 15, 2015 | Volume: 163 | Issue: 6 | Pages: 482-483

10.7326/l15-5136 | PMID 26370016 Get It

Modeling dioxygenase enzyme kinetics in familial paraganglioma
Peters, Justin P. , Her, Yeng F., Maher, L. James

Biology Open | September 15, 2015 | Volume: 4 | Issue: 10 | Pages: 1281-1289

10.1242/bio.013623 | PMID 26369930 Get It

ABSTRACT Hypoxia inducible factors (HIFs) play vital roles in cellular maintenance of oxygen homeostasis. These transcription factors are responsible for the expression of genes involved in angiogenesis, metabolism, and cell proliferation. Here, we generate a detailed mathematical model for the enzyme kinetics of α-ketoglutarate-dependent HIF prolyl 4-hydroxylase domain (PHD) dioxygenases to simulate our in vitro data showing synergistic PHD inhibition by succinate and hypoxia in experimental models of succinate dehydrogenase loss, which phenocopy familial paraganglioma. Our mathematical model confirms the inhibitory synergy of succinate and hypoxia under physiologically-relevant conditions. In agreement with our experimental data, the model predicts that HIF1α is not stabilized under atmospheric oxygen concentrations, as observed. Further, the model confirms that addition of α-ketoglutarate can reverse PHD inhibition by succinate and hypoxia in SDH-deficient cells.
Evidence‐ and consensus‐based (S3) Guidelines for the Treatment of Actinic Keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version
Werner, Ricardo Niklas , Stockfleth, Eggert , Connolly, S. M., Correia, Osvaldo, Erdmann, R., Gupta, Aditya K. , Jacobs, Anja , Kerl, H., Martin, George M. , Paquet, Maryse, Pariser, David M. , Rosumeck, Stefanie , Röwert‐Huber, Hans‐Joachim, Sahota, A., Sangüeza, Omar P., Sporbeck, Birte, Swanson, Neil A. , Torezan, Luís , Nast, Alexander , Foley, Peter Anthony , Lim, Henry W. , Shumack, Stephen P.

Journal of the European Academy of Dermatology and Venereology | September 15, 2015 | Volume: 29 | Issue: 11 | Pages: 2069-2079

10.1111/jdv.13180 | PMID 26370093 Get It

AbstractBackgroundActinic keratosis (AK) is a frequent health condition attributable to chronic exposure to ultraviolet radiation. Several treatment options are available and evidence based guidelines are missing.ObjectivesThe goal of these evidence‐ and consensus‐based guidelines was the development of treatment recommendations appropriate for different subgroups of patients presenting with AK. A secondary aim of these guidelines was the implementation of knowledge relating to the clinical background of AK, including consensus‐based recommendations for the histopathological definition, diagnosis and the assessment of patients.MethodsThe guidelines development followed a pre‐defined and structured process. For the underlying systematic literature review of interventions for AK, the methodology suggested by the Cochrane Handbook for Systematic Reviews of Interventions, the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was adapted. All recommendations were consented during a consensus conference using a formal consensus methodology. Strength of recommendations was expressed based on the GRADE approach. If expert opinion without external evidence was incorporated into the reasoning for making a certain recommendation, the rationale was provided. The Guidelines underwent open public review and approval by the commissioning societies.ResultsVarious interventions for the treatment of AK have been assessed for their efficacy. The consenting procedure led to a treatment algorithm as shown in the guidelines document. Based on expert consensus, the present guidelines present recommendations on the classification of patients, diagnosis and histopathological definition of AK. Details on the methods and results of the systematic literature review and guideline development process have been published separately.ConclusionsInternational guidelines are intended to be adapted to national or regional circumstances (regulatory approval, availability and reimbursement of treatments).
Hemodynamics during anesthesia for intra-arterial therapy of acute ischemic stroke
Jagani, Manoj, Brinjikji, Waleed , Pasternak, Jeffrey J., Kallmes, David F. , Rabinstein, Alejandro A.

Journal of NeuroInterventional Surgery | September 14, 2015 | Volume: 8 | Issue: 9 | Pages: 883-888

10.1136/neurintsurg-2015-011867 | PMID 26371294 Get It

Background and purpose Many studies have suggested a relationship between the type of anesthesia provided during intra-arterial therapy for acute ischemic stroke and patient outcomes. Variability in blood pressure and hypotension have previously been identified as possible reasons for worse outcomes in acute stroke. Our aim was to investigate hemodynamic parameters and neurological outcomes of patients receiving either general anesthesia or conscious sedation for intra-arterial therapy of acute stroke. Methods We performed a retrospective review of patients undergoing intra-arterial therapy from December 2008 to March 2015. Demographic data, baseline National Institutes of Health Stroke Scale score, preoperative physiological variables, procedural details, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate, and modified Rankin Scale scores were recorded. Results 99 patients were included in the study, with 38 receiving general anesthesia and 61 receiving conscious sedation. Patients who received general anesthesia had a lower maximum SBP (p=0.02), minimum SBP (p<0.0001), minimum DBP (p<0.0001), and minimum MAP (p<0.0001). On multivariate analysis, general anesthesia was associated with lower minimum SBP (p=0.04), DBP (p=0.02), and MAP (p=0.007). Conscious sedation was associated with more favorable neurological outcomes (p=0.02). Patients with favorable neurological outcomes had a lower maximum variability in SBP (p=0.01) and MAP (p=0.03), as well as a higher minimum DBP (p=0.03). Conclusions Patients with acute ischemic stroke undergoing intra-arterial therapy with general anesthesia had lower minimum SBP, DBP, and MAP, greater fluctuations in blood pressure, and less favorable outcomes. More studies are needed to examine the implications of variable and reduced blood pressures and neurological outcomes.
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
D’Souza, Anita , Dispenzieri, Angela , Wirk, Baldeep , Zhang, Mei-Jie , Kyle, Robert A. , Kumar, Shaji , Comenzo, Raymond L. , Cornell, Robert F. , Weiss, Brendan M. , Freytes, César O. , Scott, Emma C. , Landau, Heather , Moreb, Jan S. , Costa, Luciano J. , Ramanathan, Muthalagu , Kamble, Rammurti T., Olsson, Richard F. , Ganguly, Siddhartha , Kindwall‐Keller, Tamila L. , Hari, Parameswaran , Huang, Jiaxing, Peter Gale, Robert, Savani, Bipin N. , Vogl, Dan T. , Landau, Heather J., Callander, Natalie S. , Nishihori, Taiga , Kindwall-Keller, Tamila L, Mark, Tomer M, Zhang, Mei‐Jie , Huang, Jiaxing , Gertz, Morie A. , Gale, Robert Peter , Lazarus, Hillard M. , Wood, William A. , Mark, Tomer M , D'Souza, Anita , Dispenzieri, Angela , Olsson, Richard F , Costa, Luciano J , Hari, Parameswaran

Journal of Clinical Oncology | September 14, 2015 | Volume: 33 | Issue: 32 | Pages: 3741-3749

10.1200/jco.2015.62.4015 | PMID 26371138 Get It

Purpose Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis (AL), but it is associated with a high risk of early mortality (EM). In a multicenter randomized comparison against oral chemotherapy, autotransplantation was associated with 24% EM. We analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North America. Patients and Methods Between 1995 and 2012, 1,536 patients with AL who underwent autotransplantation at 134 centers were identified in the Center for International Blood and Marrow Transplant Research database. EM and overall survival (OS) were analyzed in three time cohorts: 1995 to 2000 (n = 140), 2001 to 2006 (n = 596), and 2007 to 2012 (n = 800). Hematologic and renal responses and factors associated with EM, relapse and/or progression, progression-free survival and OS were analyzed in more recent subgroups from 2001 to 2006 (n = 197) and from 2007 to 2012 (n = 157). Results Mortality at 30 and 100 days progressively declined over successive time periods from 11% and 20%, respectively, in 1995 to 2000 to 5% and 11%, respectively, in 2001 to 2006, and to 3% and 5%, respectively, in 2007 to 2012. Correspondingly, 5-year OS improved from 55% in 1995 to 2000 to 61% in 2001 to 2006 and to 77% in 2007 to 2012. Hematologic response to transplantation improved in the latest cohort. Renal response rate was 32%. Centers performing more than four AL transplantations per year had superior survival outcomes. In the multivariable analysis, cardiac AL was associated with high EM and inferior progression-free survival and OS. Autotransplantation in 2007 to 2012 and use of higher dosages of melphalan were associated with a lowered relapse risk. A Karnofsky score less than 80 and creatinine levels 2 mg/m2 or greater were associated with worsened OS. Conclusion Post-transplantation survival in AL has improved, with a dramatic reduction in early post-transplantation mortality and excellent 5-year survival. The risk-benefit ratio for autotransplantation has changed, and randomized comparison with nontransplantation approaches is again warranted.
Letter by Sanchis-Gomar et al Regarding Article, “Cardiac Remodeling in Response to 1 Year of Intensive Endurance Training”
Joyner, Michael J. , Lucía, Alejandro , Sanchis‐Gomar, Fabián , Joyner, Michael J

Circulation | September 14, 2015 | Volume: 132 | Issue: 11 | Pages: No page available

10.1161/circulationaha.114.013764 | PMID 26371240 Get It

Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals
Reitz, Christiane , Cheng, Rong , Jun, Gyungah , Sato, Christine , Rajbhandary, Ruchita, Wang, Li San, Lin, Chiao‐Feng , Larson, Eric B., Graff‐Radford, Neill R. , Evans, Denis A., Jager, Philip L. De , Crane, Paul K. , Buxbaum, Joseph D. , Murrell, Jill R. , Raj, Towfique , Ertekin‐Taner, Nilüfer , Logue, Mark, Baldwin, Clinton T., Green, Robert C. , Barnes, Lisa L. , Cantwell, Laura B., Fallin, M. Daniele , Go, Rodney C.P., Griffith, Patrick , Obisesan, Thomas O. , Bennett, David A. , Hendrie, Hugh C. , Hall, Kathleen, Byrd, Goldie S. , Kukull, Walter A. , Foroud, Tatiana M., Haines, Jonathan L. , Farrer, Lindsay A. , Pericak‐Vance, Margaret A. , Schellenberg, Gerard D. , Mayeux, Richard , Morris, John C. , Leverenz, James B. , DeKosky, Steven T. , Håkonarson, Håkon , Jarvik, Gail P. , Albin, Roger L. , Lyketsos, Constantine G. , Jicha, Gregory A. , Demirci, F. Yesim , Burke, James R. , Cao, Chuanhai , Carroll, Steven L. , Cribbs, David H. , Mack, Wendy J. , Sonnen, Joshua A. , Bennett, David A. , Ghani, Mahdi , Vardarajan, Badri Narayan , Naj, Adam Christian , Valladares, Otto , Manly, Jennifer J. , Lunetta, Kathryn L. , Kamboh, M. Ilyas , López, Oscar L. , Goate, Alison , Lee, Joseph H. , George‐Hyslop, Peter St , Rogaeva, Ekaterina A. , Hakonarson, Hakon , Leverenz, James B , Jarvik, Gail P , Morris, John C , Jicha, Gregory A , Sonnen, Joshua , Barnes, Lisa L

JAMA Neurology | September 14, 2015 | Volume: 72 | Issue: 11 | Pages: 1313

10.1001/jamaneurol.2015.1700 | PMID 26366463 Get It

Base Resolution Methylome Profiling: Considerations in Platform Selection, Data Preprocessing and Analysis
Sun, Zhifu , Cunningham, Julie M. , Kocher, Jean‐Pierre , Cunningham, Julie, Slager, Susan, Slager, Susan L. , Sun, Zhifu

Epigenomics | September 14, 2015 | Volume: 7 | Issue: 5 | Pages: 813-828

10.2217/epi.15.21 | PMID 26366945 Get It

Three dimensionality of gleno‐humeral deformities in obstetrical brachial plexus palsy
Mozingo, Joseph D. , Sheehan, Frances T. , Brochard, Sylvain , Alter, Katharine E.

Journal of Orthopaedic Research | September 12, 2015 | Volume: 34 | Issue: 4 | Pages: 675-682

10.1002/jor.23049 | PMID 26363273 Get It

ABSTRACTThe primary objective of this study was to test the hypothesis that gleno‐humeral deformity in children and adolescent with obstetrical brachial plexus palsy is three‐dimensional (3D). The study also compared the metrological properties of typical two‐dimensional gleno‐humeral measures to the newly developed 3D measures. Thirteen individuals (age = 11.8 ± 3.3 years) with obstetrical brachial plexus palsy participated in this IRB‐approved study. 3D axial magnetic resonance images were acquired for both shoulders. Glenoid and humeral models were created in order to quantify 3D glenoid version, humeral head migration, and glenoid concavity. Two‐dimensional (2D) measures were acquired as recommended in the literature. All measures were completed by two observers in this observer‐blind study. Compared to the non‐involved side, the glenoid was more retroverted (7.91°, p = 0.003) and inferiorly oriented (7.28°, p = 0.009). The humeral head was migrated more posteriorly (5.54 mm, p = 0.007), inferiorly (−3.96 mm, p = 0.013), and medially (−3.63 mm,p = 0.002). Eleven of the 13 glenoids were concave, based on the 3D glenoid models. The concurrent validity between three‐ and 2D measures were highly dependent of the parameter measured, the slice level used for the 2D analysis, and the presence/absence of pathology (0.63 < r < 0.91). The standard error of measurement for the 2D anterior–posterior version (>3°) was larger than that for the 3D measure of version (<1°) on the involved side. This study clearly demonstrated that the gleno‐humeral deformation in obstetrical brachial plexus palsy is 3D, emphasizing the need for 3D subject specific gleno‐humeral shape analysis for follow‐up and treatment plans in children with obstetrical brachial plexus palsy. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:675–682, 2016.
Molecular Pathways: Targeting ATR in Cancer Therapy
Karnitz, Larry M., Zou, Lee

Clinical Cancer Research | September 11, 2015 | Volume: 21 | Issue: 21 | Pages: 4780-4785

10.1158/1078-0432.ccr-15-0479 | PMID 26362996 Get It

Abstract The human ATR gene encodes a kinase that is activated by DNA damage and replication stress as a central transducer of a checkpoint signaling pathway. Once activated, ATR phosphorylates multiple substrates, including the kinase Chk1, to regulate cell-cycle progression, replication fork stability, and DNA repair. These events promote cell survival during replication stress and in cells with DNA damage. Accordingly, there has been the tantalizing possibility that ATR inhibitors would be therapeutically useful, especially if they were more effective in tumor versus normal cells. Indeed, multiple studies have demonstrated that alterations that promote tumorigenesis, such as defects in the ATM-p53 pathway, constitutive oncogene activation, and acquisition of the alternative lengthening of telomeres pathway, render tumor cells sensitive to ATR inhibitor monotherapy and/or increase the synergy between ATR inhibitors and genotoxic chemotherapies. Now, nearly two decades after the discovery of ATR, two highly selective and potent ATR inhibitors, AZD6738 and VX-970, are in early-phase clinical trials either as monotherapies or paired with a variety of genotoxic chemotherapies. These trials will generate important insights into the effects of ATR inhibition in humans and the potential role of inhibiting this kinase in the treatment of human malignancies. Clin Cancer Res; 21(21); 4780–5. ©2015 AACR.